Display options
Cite
Peppicelli S, Ruzzolini J, Andreucci E, et al. Potential Role of HLA Class I Antigens in the Glycolytic Metabolism and Motility of Melanoma Cells. Cancers (Basel). 2019;11(9)doi: 10.3390/cancers11091249.
Peppicelli, S., Ruzzolini, J., Andreucci, E., Bianchini, F., Kontos, F., Yamada, T., Ferrone, S., & Calorini, L. (2019). Potential Role of HLA Class I Antigens in the Glycolytic Metabolism and Motility of Melanoma Cells. Cancers, 11(9), . https://doi.org/10.3390/cancers11091249
Peppicelli, Silvia, et al. "Potential Role of HLA Class I Antigens in the Glycolytic Metabolism and Motility of Melanoma Cells." Cancers vol. 11,9 (2019). doi: https://doi.org/10.3390/cancers11091249
Peppicelli S, Ruzzolini J, Andreucci E, Bianchini F, Kontos F, Yamada T, Ferrone S, Calorini L. Potential Role of HLA Class I Antigens in the Glycolytic Metabolism and Motility of Melanoma Cells. Cancers (Basel). 2019 Aug 26;11(9). doi: 10.3390/cancers11091249. PMID: 31454998; PMCID: PMC6770395.
Copy Download .nbib Format: NLM
Share it on

Cancers (Basel). 2019 Aug 26;11(9). doi: 10.3390/cancers11091249.

Potential Role of HLA Class I Antigens in the Glycolytic Metabolism and Motility of Melanoma Cells.

Cancers

Silvia Peppicelli, Jessica Ruzzolini, Elena Andreucci, Francesca Bianchini, Filippos Kontos, Teppei Yamada, Soldano Ferrone, Lido Calorini

Affiliations

  1. Department of Experimental and Clinical Biomedical Sciences "Mario Serio", Section of Experimental Pathology and Oncology, Viale G.B. Morgagni, 50-50134, Florence, Italy. [email protected].
  2. Department of Experimental and Clinical Biomedical Sciences "Mario Serio", Section of Experimental Pathology and Oncology, Viale G.B. Morgagni, 50-50134, Florence, Italy.
  3. Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.
  4. Department of Experimental and Clinical Biomedical Sciences "Mario Serio", Section of Experimental Pathology and Oncology, Viale G.B. Morgagni, 50-50134, Florence, Italy. [email protected].
  5. Istituto Toscano Tumori and Center of Excellence for Research, Transfer and High Education DenoTHE University of Florence, Piazza di San Marco, 4, 50121 Florence, Italy. [email protected].

PMID: 31454998 PMCID: PMC6770395 DOI: 10.3390/cancers11091249

Abstract

Besides playing a crucial role in immune surveillance, human leukocyte antigens (HLA) possess numerous non-immune functions involved in cell communication. In the present study, screening of a panel of HLA class I- and HLA class II-specific monoclonal antibodies (mAbs) for their effects on the metabolism of human melanoma cells showed for the first time that the HLA-B,C-specific mAb B1.23.2 reduced the expression level of key glycolytic enzymes, but did not affect that of mitochondrial respiration effectors. As a result, the metabolism of melanoma cells shifted from a Warburg metabolism to a more oxidative phosphorylation. In addition, the HLA-B,C-specific mAb B1.23.2 downregulated the expression of glutamine transporter and glutaminase enzyme participating in the reduction of tricarboxylic acid cycle. The HLA-B,C-specific mAb B1.23.2-mediated reduction in energy production was associated with a reduction of melanoma cell motility. On the whole, the described results suggest that HLA class I antigens, and in particular the gene products of HLA-B and C loci play a role in the motility of melanoma cells by regulating their metabolism.

Keywords: HLA class I; glycolytic metabolism; melanoma cells; motility

Conflict of interest statement

The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the dec

References

  1. Folia Biol (Praha). 2004;50(2):35-42 - PubMed
  2. Cancer Lett. 2017 Nov 1;408:43-54 - PubMed
  3. J Cell Sci. 2000 Dec;113 Pt 23:4139-40 - PubMed
  4. Clin Cancer Res. 2004 Apr 1;10(7):2245-52 - PubMed
  5. Vascul Pharmacol. 2016 Aug;83:47-56 - PubMed
  6. J Immunol. 1988 Nov 15;141(10):3512-5 - PubMed
  7. J Oncol. 2019 Jun 2;2019:8340926 - PubMed
  8. Nat Rev Cancer. 2004 Nov;4(11):891-9 - PubMed
  9. Cancer Res. 2016 Apr 15;76(8):2231-42 - PubMed
  10. Tissue Antigens. 2003 Aug;62(2):139-48 - PubMed
  11. Cell Cycle. 2016 Jul 17;15(14):1908-18 - PubMed
  12. Science. 2009 May 22;324(5930):1029-33 - PubMed
  13. Pigment Cell Melanoma Res. 2014 Jan;27(1):3-5 - PubMed
  14. Cancer Metastasis Rev. 2014 Sep;33(2-3):823-32 - PubMed
  15. Oncotarget. 2016 Feb 9;7(6):6891-901 - PubMed
  16. Tissue Antigens. 1983 Aug;22(2):107-17 - PubMed
  17. Curr Oncol. 2012 Feb;19(1):39-41 - PubMed
  18. J Immunol Methods. 1993 May 26;161(2):239-56 - PubMed
  19. J Cell Biol. 1984 Jul;99(1 Pt 2):222s-225s - PubMed
  20. Nature. 2013 Jun 6;498(7452):109-12 - PubMed
  21. Exp Cell Res. 1977 Feb;104(2):255-62 - PubMed
  22. Eur J Pharmacol. 1997 Jun 11;328(2-3):241-8 - PubMed
  23. Proc Natl Acad Sci U S A. 1991 Aug 1;88(15):6755-9 - PubMed
  24. Methods. 2001 Dec;25(4):402-8 - PubMed
  25. Cell. 1990 Jul 27;62(2):297-307 - PubMed
  26. Proc Natl Acad Sci U S A. 1986 May;83(10):3474-8 - PubMed
  27. J Cell Biol. 1984 Feb;98(2):725-31 - PubMed
  28. J Cell Biol. 1986 Jul;103(1):215-22 - PubMed
  29. Nat Rev Cancer. 2008 Sep;8(9):705-13 - PubMed
  30. J Immunol. 2010 Jul 15;185(2):1037-44 - PubMed
  31. J Clin Invest. 1991 Jan;87(1):284-92 - PubMed
  32. Oncotarget. 2015 Jan 1;6(1):130-43 - PubMed

Publication Types

Grant support